Successful mammalian target of rapamycin inhibitor maintenance therapy following induction chemotherapy with gemcitabine and doxorubicin for metastatic sarcomatoid renal cell carcinoma

By                

Oncology Letters, Vol. 8, Iss. 1, 2014-01 ,pp. : 464-466

Spandidos Publications

Access to resources Recommend Favorite

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

By Capdevila Jaume   Salazar Ramón   Halperín Irene   Abad Albert   Yao James  

Cancer and Metastasis Reviews, Vol. 30, Iss. 1, 2011-03 ,pp. : 27-34

Springer Publishing Company

Access to resources Recommend Favorite

The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors

By  

Current Cancer Therapy Reviews, Vol. 4, Iss. 3, 2008-08 ,pp. : 227-234

Bentham Science Publishers

Access to resources Recommend Favorite

Interferonα enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity

By          

Experimental and Therapeutic Medicine, Vol. 8, Iss. 1, 2014-01 ,pp. : 267-273

Spandidos Publications

Access to resources Recommend Favorite

Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk

By Shu Xiang   Lin Jie   Wood Christopher G.   Tannir Nizar M.   Wu Xifeng  

Journal of the National Cancer Institute, Vol. 105, Iss. 6, 2013-03 ,pp. : 424-432

Oxford University Press

Access to resources Recommend Favorite